Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
18.4M
-
Number of holders
-
23
-
Total 13F shares, excl. options
-
352K
-
Shares change
-
+100K
-
Total reported value, excl. options
-
$1.94M
-
Value change
-
+$552K
-
Number of buys
-
10
-
Number of sells
-
-8
-
Price
-
$5.50
Significant Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) as of Q2 2024
27 filings reported holding CASI - CASI Pharmaceuticals, Inc. - Ordinary Shares as of Q2 2024.
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) has 23 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 352K shares
of 18.4M outstanding shares and own 1.91% of the company stock.
Largest 10 shareholders include VR Adviser, LLC (112K shares), Wellington Shields Capital Management, LLC (89.2K shares), Wellington Shields & Co., LLC (43.1K shares), RENAISSANCE TECHNOLOGIES LLC (40.8K shares), GEODE CAPITAL MANAGEMENT, LLC (22.2K shares), HOWLAND CAPITAL MANAGEMENT LLC (15.1K shares), UBS Group AG (11.3K shares), ADAR1 Capital Management, LLC (8.24K shares), Royal Bank of Canada (6.9K shares), and MORGAN STANLEY (1.44K shares).
This table shows the top 23 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.